CCA

February 2, 2021 · Brielle Gregory Collins, ASCO staff
ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors. Read More >>
ASCO ® Clinical Cancer Advances 2020
February 4, 2020 · Brielle Gregory, ASCO staff
The 2020 Advance of the Year in ASCO’s Clinical Cancer Advances report is the refinement of surgical treatment of cancer. Read More >>
ASCO ® American Society of Clinical Oncology; Clinical Cancer Advances 2019: ASCO's Annual Report on Progress Against Cancer
January 31, 2019 · Greg Guthrie, ASCO Staff
In 2019, ASCO recognizes the progress in treating rare cancers as the Advance of the Year. Impressive progress has been made in bringing new treatment advances to cancers that are rare and difficult to treat. This year’s Clinical Cancer Advances report describes emerging treatments for thyroid cancer, uterine cancer, desmoid tumor, neuroendocrine tumor, and tenosynovial giant cell tumor. Read More >>
American Society of Clinical Oncology; Clinical Cancer Advances 2018: ASCO's Annual Report on Progress Against Cancer
January 30, 2018 · Greg Guthrie, ASCO staff
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits? Read More >>
2017 Clinical Cancer Advances
February 1, 2017 · Greg Guthrie, ASCO staff
The 2017 Clinical Cancer Advances report of the American Society of Clinical Oncology has announced that the Advance of the Year is Immunotherapy 2.0. Why 2.0? Because the role of immunotherapy in cancer care is expanding, and oncologists are learning how to use it more effectively. Read More >>

Pages